Drug intelligence / Profile preview

[68Ga]Ga-NOTA-G2

Development stage: Preclinical
Lead developer: Centre Eugene Marquis
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-NOTA-G2 is a **gallium-68-labeled radiopharmaceutical** constructed by chelating the positron-emitting radioisotope gallium-68 (^68Ga) using the NOTA chelator and conjugating it to the G2 targeting vector. The NOTA chelator is widely used for ^68Ga radiopharmacy as it forms stable complexes with gallium and allows efficient radiolabeling[2][4]. ^68Ga-NOTA-G2 is primarily developed for positron emission tomography (PET) imaging, intended to target specific molecular biomarkers, typically enabling visualization of target receptor-positive tumors or disease tissue. This agent binds to its molecular target (specificity for G2’s target should be confirmed in literature, but generally NOTA-based tracers target receptors such as somatostatin, PSMA, VCAM-1, etc.), delivers the β+ emitting ^68Ga for high-resolution PET detection, and is eliminated rapidly from non-target tissues to increase contrast. It is investigational and generally under preclinical or early clinical development for molecular imaging applications.[2][4]

Brand names: [68Ga]Ga-NOTA-G2
Other names: [68Ga]Ga-NOTA-G2

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on [68Ga]Ga-NOTA-G2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-NOTA-G2.

Explore the full profile